Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus CCRT for Locally Advanced Cervical Cancer
NCT06256224Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of toripalimab in cervical squamous cell carcinoma (CSCC) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: 2-year progression-free survival. Started Feb 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT06256224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256224.